A randomized Phase II trial of echinomycin, trimetrexate, and cisplatin plus etoposide in patients with metastatic nonsmall cell lung carcinoma
Authors:
Open Access
Abstract
BACKGROUND Patients with metastatic nonsmall cell lung carcinoma (NSCLC) usually have a poor prognosis. A chemotherapy regimen containing cisplatin is commonly used for symptom palliation. Echinomycin is a potent bifunctional intercalator of double‐strand DNA; trimetrexate is a new derivative of methotrexate and is active against methotrexate‐resistant tumor cells in vitro. METHODS The Eastern Cooperative Oncology Group conducted a randomized Phase II study. Eligible patients were assigned to receive echinomycin 1200 μg/m2 by intravenous (i.v.) infusion over 30‐60 minutes once a week for 4 weeks, repeated every 6 weeks; trimetrexate 12 mg/m2 i.v. bolus on Days 1‐5 every 3 weeks, or 8 mg/m2 i.v. bolus on Days 1‐5 for patients who had prior radiation to greater than 30% of their bone marrow; or cisplatin 60 mg/m2 i.v. on Day 1 and etoposide 120 mg/m2 i.v. on Days 1‐3 every 4 weeks. Patients were evaluated before each cycle for tumor response, toxicity, and quality‐of‐life measurements. RESULTS One hundred thirty‐six patients were entered on the study, and 118 were evaluable for toxicity and response. The response rates were 16%, 5%, and 5% in patients treated with cisplatin and etoposide, echinomycin, and trimetrexate, respectively. There were no complete responses. The median survival was 37.9, 24.3, and 28.0 weeks for patients who received cisplatin and etoposide, echinomycin, and trimetrexate, respectively. Although cisplatin and etoposide appeared to give better therapeutic results, the response rate or survival did not reach statistical significance. This may have been due to inadequate sample size. Neither did quality‐of‐life measurement show any significant differences among treatments. CONCLUSIONS Echinomycin and trimetrexate had minimal antitumor activity in patients with metastatic NSCLC. Response rate and survival remained poor in all three treatment arms. Patients should be encouraged to participate in clinical trials so that more effective therapy can be identified. Cancer 1998;82:292‐300. © 1998 American Cancer Society.Keywords
This publication has 17 references indexed in Scilit:
- Trial of sequential trimetrexate, fluorouracil, and high-dose leucovorin in previously treated patients with gastrointestinal carcinoma.Journal of Clinical Oncology, 1994
- Trimetrexate: A Critical Appraisal of the Phase II Clinical Trial Experience: Evidence of Drug Discovery-Clinical Development DisjunctionCancer Investigation, 1994
- Polychemotherapy in advanced non small cell lung cancer: a meta-analysisThe Lancet, 1993
- A randomized study comparing cisplatin or carboplatin with etoposide in patients with advanced non-small-cell lung cancer: European Organization for Research and Treatment of Cancer Protocol 07861.Journal of Clinical Oncology, 1990
- Chemotherapy can prolong survival in patients with advanced non-small-cell lung cancer--report of a Canadian multicenter randomized trial.Journal of Clinical Oncology, 1988
- A randomized trial of the four most active regimens for metastatic non-small-cell lung cancer.Journal of Clinical Oncology, 1986
- Echinomycin: The first bifunctional intercalating agent in clinical trialsInvestigational New Drugs, 1985
- Trimetrexate: a new antifol entering clinical trialsInvestigational New Drugs, 1985
- Design and analysis of randomized clinical trials requiring prolonged observation of each patient. I. Introduction and designBritish Journal of Cancer, 1976
- Use of Ranks in One-Criterion Variance AnalysisJournal of the American Statistical Association, 1952